Tezampanel, a non opium based pain killer by Raptor Pharmaceutical Corporation, has been found effective in dealing with acute migraine and other neuropathic pain.
Onsolis to treat breakthrough cancer pain has been launched in US by Meda Pharmaceuticals Inc.
Ralfinamide from Newron, which promises the least side-effects, is on way; Pfizer, AstraZeneca & Merck are exploring potential drugs to block the Nav1.7 channel.
The diclofenac 75mg / 1ml injection is used to manage acute pain.
Piramal Healthcare Ltd has launched a bioelectronics product, ActiPatch, for pain management in India.